Pamorelin Drug Interactions

Drugs affecting pituitary secretion of gonadotropins: Caution should be exercised when drugs that affect the pituitary secretion of gonadotropins are concomitantly used with triptorelin. Monitoring of the patient's hormonal status is also recommended.
Drugs that induce hyperprolactinemia [e.g., antipsychotic agents (chlorpromazine, haloperidol, molindone, olanzapine, prochlorperazine, risperidone), methyldopa, metoclopramide, reserpine]: Since the number of GnRH receptors is decreased in patients with hyperprolactinemia, drugs that induce hyperprolactinemia may reduce the efficacy of triptorelin. The concomitant use of these drugs with triptorelin is not recommended.
Drugs that prolong QTc interval and induce Torsades de pointes: Androgen deprivation treatment may prolong QTc interval. Thus, the concomitant use of triptorelin with drugs that prolong the QTc interval and induce Torsades de pointes should be carefully evaluated. Such drugs include but are not limited to the following examples: Class IA (e.g., quinidine, disopyramide), Class III (e.g. amiodarone, sotalol, dofetilide, ibutilide, dropedarone), or Class IC (e.g., flecainide, propafenone) antiarrhythmic drugs, antipsychotics (e.g., chlorpromazine), antibiotics and analogues (e.g., erythromycin, clarithromycin, azithromycin), quinolone antibiotics (e.g., moxifloxacin), antimalarials (e.g., quinine), azole antifungals, 5-hydroxytrypt amine (5-HT3) receptor antagonists (e.g., ondansetron), methadone, and beta-2 adrenoceptor agonists (e.g., salbutamol).
Anticoagulants: Since there is a potential risk of hematoma at the injection site, intramuscular triptorelin should be used in caution in patients treated with anticoagulants.
Antihypertensives: Adjustments of antihypertensive therapy may be required in patients receiving triptorelin.
Laboratory test alterations: Chronic or continuous administration of triptorelin in therapeutic doses results in suppression of pituitary-gonadal axis. Normal function of the pituitary-gonadal axis is usually restored within 4 to 12 weeks after treatment discontinuation. Thus, diagnostic tests of the pituitary-gonadal function conducted during treatment and within 4 to 12 weeks after cessation of therapy may be misleading.
Decreased hemoglobin and red blood cell count, and increased glucose, blood urea nitrogen (BUN), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase levels were reported. Majority of the changes were mild to moderate.